Who Owns Bridgebio Pharma Inc (BBIO)? 13F Institutional Holders (Q2 2026)

BBIO ranks #1234 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

BBIO is a disclosed holding of Andreas Halvorsen (Viking Global Investors), one of the tracked superinvestors on AlphaSMO — it makes up 2.1% of that fund's own 13F portfolio.

BBIO is a top-conviction position for Aisling Capital Management LP — at 72.5% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

The largest dollar stake in BBIO belongs to Jupiter Topco LLC, but the position matters far more to Aisling Capital Management LP, who has 72.5% of their own portfolio riding on it — a reminder that the biggest holder by size and the holder with the biggest bet aren't always the same fund.

Ken Griffin has added to its BBIO position for two straight quarters, increasing it by $226.1M to reach $322.3M today.

Andreas Halvorsen has trimmed its BBIO position for two straight quarters, cutting it by $360.0M while still holding $741.0M.

BBIO is down 0.1% today, but institutions show net buying of $1.3B this quarter — a divergence between today's price move and the underlying institutional flow.

BBIO reported a net loss of $702.0M over the trailing twelve months.

• Not yet profitable — net loss of $702.0M over the trailing twelve months
• Revenue grew 202.4% year over year
• Net income improved year over year, from -$785.0M to -$702.0M
• Operating cash flow was negative, using $445.9M in cash
• Current ratio of 2.77x — enough short-term assets to cover short-term liabilities